Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed) | PAR 24 198

Opportunity Information: Apply for PAR 24 198

The NIH funding opportunity PAR-24-198 is an R01 grant aimed at reducing amyloid-related imaging abnormalities (ARIA) that can occur after passive anti-amyloid beta immunotherapy, a treatment approach used in the Alzheimer disease space. The central focus is not on running a clinical trial, but on building a deeper, mechanistic understanding of what happens to brain blood vessels and the blood-brain barrier (BBB) when anti-amyloid beta antibodies interact with amyloid in or around cerebral vessels. The initiative is meant to push research that explains the cellular and molecular responses driving ARIA, so that researchers can identify actionable targets and develop protective strategies that keep the BBB and cerebrovascular system more stable during amyloid-targeting therapies.

Scientifically, the opportunity is framed around the idea that ARIA reflects adverse vascular and BBB-related responses to immunotherapy, and that these responses are likely governed by specific molecular pathways in cells that make up the neurovascular unit. Applications are expected to dig into the mechanisms behind vessel and BBB dysfunction in this context, such as how antibody-mediated amyloid clearance affects vascular integrity, inflammation, immune cell interactions, endothelial function, perivascular drainage, or other relevant processes that could lead to edema or microhemorrhages seen on imaging. The intended outcome is a clearer map of the pathways that can be targeted to prevent or lessen ARIA risk, ultimately enabling safer therapeutic interventions directed at beta-amyloid.

From a program design standpoint, this is a discretionary, NIH-sponsored grant using the R01 mechanism, and it is explicitly labeled “Clinical Trial Not Allowed,” meaning the work should be preclinical and/or mechanistic rather than interventional studies in humans that meet NIH’s definition of a clinical trial. It falls under the broader health research funding activity category and is associated with CFDA numbers 93.853 and 93.866. The listed award ceiling is $500,000, and the original closing date provided is 2024-11-05. While the expected number of awards is not specified in the provided data, the structure and ceiling suggest NIH is supporting substantial, hypothesis-driven projects that can generate rigorous mechanistic insight and identify concrete protective targets or strategies.

Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments that are federally recognized; Native American tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in that category description); for-profit organizations other than small businesses; and small businesses. The announcement also highlights other eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.

At the same time, the opportunity places clear limits on foreign participation. Non-domestic (non-U.S.) entities are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible to apply. However, “foreign components,” as defined by the NIH Grants Policy Statement, are allowed, which typically means a U.S. applicant organization can include certain well-justified international elements within the project as a component of the overall work, provided NIH policy requirements are met.

Overall, PAR-24-198 is best read as a targeted call for mechanistic, BBB- and cerebrovascular-focused research that explains why ARIA happens in the setting of passive anti-amyloid beta immunotherapy and how to prevent it. The emphasis is on discovery and target identification: understanding vessel and BBB biology at the molecular and cellular levels so future therapeutic strategies can incorporate protective approaches that reduce imaging abnormalities and improve the safety profile of amyloid-directed treatments.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853, 93.866.
• This funding opportunity was created on 2024-04-10.
• Applicants must submit their applications by 2024-11-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 24 198

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: